Albany, NY -- (SBWIRE) -- 07/14/2017 -- Psoriasis is an autoimmune disease that produces plaques of thickened, scaling skin which are typically red, itchy, and scaly. They may vary in severity from localized and small to complete body coverage. Skin injury can cause psoriatic skin changes at that spot. Obesity, diabetes, and heart disease are more common in people with psoriasis. Psoriasis can be initiated by certain environmental triggers. The quality of life of patients with psoriasis is often reduced because of the look of their skin. Psoriasis can be seen in people of any age, from small children to adults, most frequently patients are first diagnosed in their initial adult years. Psoriasis is linked to pathogenesis caused by dysregulation of T-cell-dependent immune response, as well as hyperproliferation of keratinocytes, the predominant cell type on the outer layer of skin.

Obtain Report Details: http://www.transparencymarketresearch.com/psoriasis-market.html

Psoriasis affects skin over the elbows, knees, and scalp and is often itchy. Although any area may be involved, it tends to be more common at sites of friction, scratching, or abrasion. Sometimes pulling off one of these small dry white flakes of skin causes a tiny blood spot on the skin. This is a special diagnostic sign in psoriasis called the Auspitz sign. The introduction of systemic therapies likely to drive the market. However, systemic therapies cannot be provided to various patients such as individuals with liver or kidney disease, pregnant women and nursing mothers. Thus, there is a unmet need existed for the new therapies that can are safe for long-term use and drugs that are in pipeline. According to World Health Organization, the prevalence of psoriasis in countries ranges between 0.09% (2) and 11.4% (3), making psoriasis a serious global problem. Between 1.3% and 34.7% of individuals with psoriasis develop chronic, inflammatory arthritis (psoriatic arthritis) that leads to joint deformations and disability.

The psoriasis market has been segmented by type, by distribution channel and by geography. In terms of type, the psoriasis has been categorized into psoriasis vulgaris, guttate psoriasis (small, drop-like spots), inverse psoriasis (in the folds like of the underarms, navel, groin, and buttocks), and pustular psoriasis (small pus-filled yellowish blisters). Psoriasis vulgaris is the most common type of psoriasis. For the treatment of psoriasis there are six FDA-approved biologics for the treatment of psoriasis belonging to three separate drug classes: Enbrel (etanercept), TNF-? inhibitors including Humira (adalimumab), the IL-17 inhibitors Cosentyx (secukinumab, Novartis), Remicade (infliximab), Taltz (ixekizumab) and the IL-12/23 inhibitor Stelara (ustekinumab). Psoriasis market is also segmented on the basis of distribution channel which comprises, supermarket/ hypermarket, grocery stores, convenience stores, online and others.

Fill the form for an exclusive sample of this report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=16445

Geographically, North America was observed to be the largest psoriasis market due high prevalence of psoriasis. According to American Academy of Dermatology, approximately 7.5 million people in the United States have psoriasis. The most common form of psoriasis, affecting about 80 to 90 percent of psoriasis patients, is plaque psoriasis. It is characterized by patches of raised, reddish skin covered with silvery-white scale. Europe is also significantly affected by psoriasis. According to World Health Organization, Psoriasis was a significant problem for 15% of patients with mild psoriasis, 23% with moderate psoriasis and 51% with severe psoriasis. In addition, 48% of patients reported that their disability due to psoriasis had a modest impact on activities of daily living. China, Japan and India likely to drive the psoriasis market in Asia Pacific

In Latin America, Brazil and Mexico are the regions that have significant potential for growth due to evolving medical structure, and high disposable income.

The major players operating in this market include Johnson & Johnson, AbbVie, AMGen, Novartis International AG, Pfizer Inc., Eli Lilly and Company, Merck & Co., Inc., LEO Pharma A/S, Celgene Corporation, Can-Fite Biopharma Inc.

The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.